Lesson plan
Taselisib
Taselisib (development code: GDC-0032) is a former cancer drug candidate that was in development by Roche. It is a small molecule phosphoinositide 3-kinase inhibitor targeting the PI3K isoform p110α (PIK3CA). Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study. Currently running clinical trials were continued for patients exhibiting benefit.
Article summary
Taselisib (development code: GDC-0032) is a former cancer drug candidate that was in development by Roche. It is a small molecule phosphoinositide 3-kinase inhibitor targeting the PI3K isoform p110α (PIK3CA). Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study. Currently running clinical trials were continued for patients exhibiting benefit.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.